New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:53 EDTATRCAtriCure price target raised to $25 from $20 at Leerink
Leerink raised its price target for AtriCure shares to $25 citing the company's strong Q4 preannouncement. The firm believes the company's momentum is sustainable into 2014 and keeps an Outperform rating on the name.
News For ATRC From The Last 14 Days
Check below for free stories on ATRC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
11:07 EDTATRCLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
July 25, 2014
08:30 EDTATRCAtriCure posted outstanding Q2 results, says Canaccord
Subscribe for More Information
July 24, 2014
16:33 EDTATRCAtriCure raises FY14 revenue view to $103M-$105M from $101M-$104M
FY14 consensus $102.57M. Consistent with the guidance provided in February, adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $9M-$10M for 2014, of which approximately $3.5M of expense will be related to the Estech transaction. AtriCure expects the Estech transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond.
16:31 EDTATRCAtriCure reports Q2 EPS (10c), consensus (19c)
Reports Q2 revenue $26.5M, consensus $25.03M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use